Presentation at ECR
March 10 2008 - 3:05AM
RNS Non-Regulatory
Medicsight Plc
10 March 2008
Press Release 10 March 2008
Medicsight PLC
("Medicsight" or "the Company")
Presentation of new data at the European Congress of Radiology (ECR)
Medicsight PLC (AIM:MDST), industry leader in the development of Computer-Aided
Detection (CAD) and image analysis software which assists in the early detection
and diagnosis of disease, is pleased to announce that yesterday it presented two
abstracts at the 2008 European Congress of Radiology at the Austria Centre in
Vienna. The abstracts are entitled "CT colonography: computer-aided detection of
morphologically flat T1 colonic carcinoma" and "CT colonography and computer
aided detection: effect of false positives on reader specificity and reading
efficiency in a low prevalence screening population". Both abstracts were
presented during the CT Colonography session (session number SS 1001b).
Medicsight is committed to ongoing clinical research demonstrating the
performance of its ColonCADTM software. The first abstract refers to research
demonstrating the effective use of ColonCADTM for the detection of flat colonic
lesions, which can be very difficult to visualise and are technically
challenging for all CAD systems. CAD systems for colorectal cancer have
therefore tended to focus on the detection of polyps, which are generally more
rounded and protuberant and thus easier to visualise. In this retrospective
study, ColonCADTM successfully identified a high proportion of flat lesions
previously verified by endoscopy.
The second abstract refers to a study examining the influence of false positives
on reader specificity in CT colonography involving CAD. All CAD systems generate
some false positives, especially at high sensitivity settings, and this has led
to a general perception among radiologists that this detracts from the
usefulness of CAD software. However in this study there was no correlation
between the number of false positives and the reader's ability to successfully
detect lesions.
- ENDS -
For further information:
Medicsight PLC
David Sumner Tel: +44 (0) 20 7605 7950
www.medicsight.com
Collins Stewart Europe Limited
Tim Mickley Tel: +44 (0) 20 7523 8350
Jonny Sloan Tel: +44 (0) 20 7523 8302
Media enquiries:
Abchurch
Ashley Tapp/ Stephanie Cuthbert Tel: +44 (0) 20 7398 7718
stephanie.cuthbert@abchurch-group.com www.abchurch-group.com
Notes to editors
Medicsight PLC is a UK-headquartered, research driven, leading developer of
computer-aided detection (CAD) and image analysis software for the medical
imaging market. The CAD software automatically highlights suspicious areas on
computerised tomography (CT) scans of the colon and lung, helping radiologists
to identify, measure and analyse potential disease and early indicators of
disease. Medicsight's computer-aided detection (CAD) software has been validated
using one of the world's largest and most population diverse databases of
verified patient CT scan data. Medicsight's ColonCADTM and LungCADTM software
products are seamlessly integrated with the advanced 3D visualisation
workstations of several industry-leading imaging equipment partners.
About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as
Multi-Detector CT scanners, radiologists are facing a growing challenge in the
amount of detailed patient image data that they must review for each patient
examination. Some CT scan examinations generate as many as 1000 images per
patient. Review of this data by the radiologist is not only time-consuming but
also prone to error due to reader fatigue. CAD software can help the reviewing
radiologist by analysing the image data and automatically highlighting
suspicious regions of interest for closer inspection. Without CAD software some
potential abnormalities or areas of disease may be overlooked. This is critical
for diagnosis and the management of patient outcomes as early detection of
disease greatly increases the probability of successful treatment and a positive
therapeutic outcome.
About Medicsight's CAD software
Medicsight's ColonCADTM and LungCADTM software use an advanced CAD algorithm to
analyse CT scans of the colon and lung and automatically highlight suspicious
areas that may be indicators of disease. CAD may highlight areas easily
overlooked by the reviewing radiologist, such as small lesions or regions that
are hidden from view behind folds in the colon or normal structures and
surrounding tissue in the lung.
Both CAD products seamlessly integrate with the advanced 3D visualisation
platforms of industry-leading imaging equipment partners. The integrated systems
provide sophisticated image viewing capabilities, including 3D reconstructed
image data, with the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of disease. This allows
clinical end users to perform either a 'second read', where CAD findings are
displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's
initial review of the original CT scan images.
Since inception, Medicsight has developed close and lasting relationships with
some of the world's foremost clinicians in product related areas. This provides
the Company with a wealth of clinical expertise and dedicated clinical research
to support ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research programmes
worldwide to develop the Company's comprehensive database of population diverse
verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASSEFWWSASEFD
Medicsight (LSE:MDST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medicsight (LSE:MDST)
Historical Stock Chart
From Jul 2023 to Jul 2024
